JP2023505189A5 - - Google Patents

Info

Publication number
JP2023505189A5
JP2023505189A5 JP2022533344A JP2022533344A JP2023505189A5 JP 2023505189 A5 JP2023505189 A5 JP 2023505189A5 JP 2022533344 A JP2022533344 A JP 2022533344A JP 2022533344 A JP2022533344 A JP 2022533344A JP 2023505189 A5 JP2023505189 A5 JP 2023505189A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
administration
bumetanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533344A
Other languages
English (en)
Japanese (ja)
Other versions
JP7885121B2 (ja
JP2023505189A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063491 external-priority patent/WO2021113775A1/en
Publication of JP2023505189A publication Critical patent/JP2023505189A/ja
Publication of JP2023505189A5 publication Critical patent/JP2023505189A5/ja
Priority to JP2025281644A priority Critical patent/JP2026076167A/ja
Application granted granted Critical
Publication of JP7885121B2 publication Critical patent/JP7885121B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533344A 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 Active JP7885121B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025281644A JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943638P 2019-12-04 2019-12-04
US62/943,638 2019-12-04
PCT/US2020/063491 WO2021113775A1 (en) 2019-12-04 2020-12-04 Methods and compositions for treating edema refractory to oral diuretics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025281644A Division JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2023505189A JP2023505189A (ja) 2023-02-08
JP2023505189A5 true JP2023505189A5 (cg-RX-API-DMAC10.html) 2023-12-12
JP7885121B2 JP7885121B2 (ja) 2026-07-06

Family

ID=76209409

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533344A Active JP7885121B2 (ja) 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物
JP2025281644A Pending JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025281644A Pending JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Country Status (10)

Country Link
US (5) US11123319B2 (cg-RX-API-DMAC10.html)
EP (1) EP4069222A4 (cg-RX-API-DMAC10.html)
JP (2) JP7885121B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220113436A (cg-RX-API-DMAC10.html)
CN (1) CN115023223A (cg-RX-API-DMAC10.html)
AU (1) AU2020397176A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010879A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160278A1 (cg-RX-API-DMAC10.html)
IL (1) IL293429A (cg-RX-API-DMAC10.html)
WO (1) WO2021113775A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法
JP2024526357A (ja) * 2021-07-16 2024-07-17 ドリペル ビー．ブイ． 水性ブメタニド含有液体
IL313921A (en) * 2021-12-30 2024-08-01 Neuropro Therapeutics Inc Pharmaceutical composition
CN115645363B (zh) * 2022-10-31 2025-06-10 浙江普利药业有限公司 一种布美他尼注射液及其制备方法
WO2026017600A1 (en) 2024-07-15 2026-01-22 Dripel B.V. Aqueous bumetanide-containing liquid
WO2026043819A1 (en) * 2024-08-19 2026-02-26 Strategic Drug Solutions, Inc. Formulations and methods for convenient and rapid diuresis for the treatment of edema

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
EP2389371A4 (en) * 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物
AU2012250050B2 (en) * 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20150239832A1 (en) * 2012-09-04 2015-08-27 Neuro Pro Therapeutics, Inc. Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use
KR20160091348A (ko) * 2014-06-08 2016-08-02 오토텔릭 엘엘씨 부종없이 통증을 완화시키기 위한 고정된 용량의 복합제
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics
JP2024520788A (ja) 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Similar Documents

Publication Publication Date Title
US20230112834A1 (en) Parenteral formulations of treprostinil
JP2517293B2 (ja) 細胞、組織修復剤
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
ES2244418T3 (es) Composiciones de apomorfina y sidenalfilo y utilizacion de los mismos para el tratamiento de la disfuncion erectil.
JPH013193A (ja) 細胞、組織修復剤
JP4827725B2 (ja) 医薬品組成物
JP2007532663A (ja) ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用
EP0296236A1 (en) Nasal delivery of caffeine
WO2012000377A1 (zh) 包含左卡尼汀和羟苯磺酸盐的药物组合物
US20240269238A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
US4789660A (en) Insulin administration using methyl and propyl paraben
US3922340A (en) Pharmaceutical compositions for treating lung diseases
EA006015B1 (ru) Содержащая циклезонид фармацевтическая композиция, предназначенная для нанесения на слизистую оболочку
JP6491191B2 (ja) 咽喉炎、嗄声及び関連の空咳、並びに口腔及び咽頭腔の炎症性疾患の治療用ロゼンジ剤
JP2012532852A (ja) ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物
WO2002024202A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
JP2024531685A5 (cg-RX-API-DMAC10.html)
JP2024520788A5 (cg-RX-API-DMAC10.html)
EA025203B1 (ru) Фармацевтический состав для назального применения, содержащий флутиказон
US20180344696A1 (en) Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations
JP2577016B2 (ja) 消化管疾患治療剤
WO2005049053A1 (en) Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction
CN108853093A (zh) 局部给药型的吞咽障碍改善用药物
NZ201683A (en) Pharmaceutical compositions comprising human proinsulin
ES2938574T3 (es) Péptido para la prevención o el tratamiento de la COVID-19